{"id":2377,"date":"2019-10-05T21:59:40","date_gmt":"2019-10-05T19:59:40","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2377"},"modified":"2024-04-10T15:28:04","modified_gmt":"2024-04-10T13:28:04","slug":"angiogenesis-tumoral-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/es\/investigacion\/area-de-cancer\/programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell\/angiogenesis-tumoral-2\/","title":{"rendered":"Angiog\u00e9nesis Tumoral"},"content":{"rendered":"\n
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes Sanchez E, Xi YX, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O’Farrell AC, Modave E, Lambrechts D, ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang BL, Roth JA, Meric Bernstam F, Herlyn M, Davies MA, Ding L, Li SQ, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JFH, PDXNET C, EurOPDX C, CASANOVAS O, GONZALEZ SUAREZ E, MU\u00d1OZ MORUNO P, VILLANUEVA GARATACHEA A. Nature Genet. 2021;53(1):doi:10.1038\/s41588-020-00750-6. IF:38,33.<\/p>\n
Moserle, Lidia; Pons, Roser; Martinez-Lozano, Mar; Jimenez-Valerio, Gabriela A.; Vidal, August; Suarez, Cristina; Trilla, Enrique; Jimenez, Jose; de Torres, Ines; Carles, Joan; Senserrich, Jordi; Aguilar, Susana; Palomero, Luis; Amadori, Alberto; Casanovas, Oriol<\/p>\n
EMBO MOLECULAR MEDICINE. 2020, doi: 10.15252\/emmm.201911889<\/p>\n
Zuazo-Gaztelu, Iratxe; Paez-Ribes, Marta; Carrasco, Patricia; Martin-Mitjana, Laura; Sallaberry, Julia; Martinez, Alba; Casanovas, Oriol<\/p>\n
NEUROENDOCRINOLOGY. 2020, doi: 10.1159\/000506496<\/p>\n
Zuazo-Gaztelu I, P\u00e0ez-Ribes M, Carrasco P, Mart\u00edn L, Soler A, Mart\u00ednez-Lozano M, Pons R, Llena J, Palomero L, Graupera M, Casanovas O<\/p>\n
CANCERS. 2020, doi: 10.3390\/cancers12020300<\/p>\n
20MEC018. Targeteando la Coagulaci\u00f3n en la formaci\u00f3n de met\u00e1stasis en c\u00e1ncer renal. Ministerio de Ciencia e Innovaci\u00f3n<\/strong>. Budget: 145200. 2020-2023. PI: Casanovas Casanovas, Oriol.<\/p>\n 20MAR004. Identification of Kidney Cancer progression targets and biomarkers through CRISPRengineered organoids and xenograft mouse models<\/strong>. Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 136250. 2020-2023. PI: Casanovas Casanovas, Oriol.<\/p>\n AEC21003. Angiotheragnostics (AtG): Developing a First-in-Class anticancer treatment with its patient selection biomarker for patients with advanced kidney cancer<\/strong>. Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer (AECC). Budget: 180000. 2021-2023. PI: Casanovas Casanovas, Oriol.<\/p>\n FIS21102. ANGIOTHERAGNOSTICS: DESARROLLO DE UN NUEVO TRATAMIENTO CON SU BIOMARCADOR DE SELECCI\u00d3N DE PACIENTES PARA PACIENTES CON C\u00c1NCER COLORECTAL AVANZADO<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 149600. 2022-2023. PI: Casanovas Casanovas, Oriol.<\/p>\n MCI21016. Desarrollo de un nuevo biomarcador y su ‘kit’ prototipo para predecir la Respuesta Agresiva en Cancer<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 132250. 2021-2023. PI: Casanovas Casanovas, Oriol.<\/p>\n\t\t\t\t\tTransferencia de tecnolog\u00eda<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT041: \u00abPD-ECGF AS BIOMARKER OF CANCER\u00bb Beca Proof of Concept (PoC) 2015 de l’European Research Council – Oriol Casanovas.<\/p>\nMapping the pathogenesis of vascular malformation<\/strong>s Angiog\u00e9nesis Tumoral Resumen Nuestro grupo de investigaci\u00f3n en el Programa ProCURE (Instituto Catal\u00e1n de Oncolog\u00eda) y el Programa OncoBell (IDIBELL) se centra en determinar las consecuencias de la adaptaci\u00f3n y la resistencia a la terapia contra el c\u00e1ncer antiangiog\u00e9nico. Para ello, utilizamos la investigaci\u00f3n traslacional en modelos murinos de c\u00e1ncer, particularmente los modelos PDOX de […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-11 14:21:17","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/2377"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=2377"}],"version-history":[{"count":6,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/2377\/revisions"}],"predecessor-version":[{"id":24135,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/2377\/revisions\/24135"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=2377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Oriol Casanovas
\nEP15382109\nPAT080-\u00abMETHODS FOR PREDICTING THE RISK OF LOCAL INVASION AND\/OR METASTASIS INDUCED BY AN ANTIANGIOGENIC TREATMENT\u00bb
\nIP: Oriol Casanovas
\nEP20382600\nPAT088: PYRIMIDINE-1,3-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF
\nCANCER
\nIP: Oriol Casanovas
\nEP23382217\nLicense: PD- ECGF AS BIOMARKER OF CANCER
\nPI: Dr. Oriol Casanovas\nSpin-off: AtG Therapeutics
\nPI: Dr. Oriol Casanovas\n\t\t\t\t\tM\u00e1s informaci\u00f3n<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t
\nIP:\u00a0Graupera Garcia-Mila, Mariona (Project Leader)
\nSocios: Centro Nacional de Investigaciones Cardiovasculares-CNIC (Dr. R. Benedito), Hospital Santa Creu Sant Pau (Dra. E. Baselga) i Sant Joan de D\u00e9u (Dr. J. Mora)
\nConvocatoria: Health Research 2018 Call for proposals, expediente: HR18-00120
\nEntidad Financiadora: Fundaci\u00f3 \u00abla Caixa\u00bb
\n\n\t\t\t\t\n\n\t\tCasanovas Casanovas, Oriol\n\t<\/h4>\n
\n\t\t\n\t\tocasanovas@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadores principales\n\t<\/h2>\n\t\t\t\t\n
\n\t\tCasanovas Casanovas, Oriol\n\t<\/h4>\n
\n\t\t\n\t\tocasanovas@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLACES RELACIONADOS\n\t<\/h4>\n
\n\t\t\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@AngioTxDx\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquipo\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tJefes\/as de grupo\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as postdoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as predoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSoporte cient\u00edfico\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tColaboradores\/as\t\t\t\t<\/a>\n\t\t\t\t\t\tJefes\/as de grupo\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n\t\tNoticias relacionadas\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\t\u00bfC\u00f3mo la terapia antiagiog\u00e9nica puede aumentar la agresividad de los tumores?<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/03\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL recibe m\u00e1s de un mill\u00f3n y medio de euros de la AECC para financiar proyectos de investigaci\u00f3n contra el c\u00e1ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLos modelos animales de xenograft recapitulan el comportamiento gen\u00e9tico de los tumores humanos originales<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t28\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentificado un biomarcador que prev\u00e9 el incremento de malignidad que puede causar la terapia antiangiog\u00e9nica en los c\u00e1nceres renales<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t05\/11\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa Marat\u00f3 impulsa 43 proyectos sobre el c\u00e1ncer en la inversi\u00f3n anual en investigaci\u00f3n m\u00e1s grande de su historia<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t31\/10\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tSant Joan de D\u00e9u y el IDIBELL unen fuerzas para crear el primer modelo animal del S\u00edndrome Sturge-Weber<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t21\/10\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTres investigadoras IDIBELL reciben ayudas de la Fundaci\u00f3n Bancaria \u00abla Caixa\u00bb para impulsar proyectos de investigaci\u00f3n pionera y de gran impacto social<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/09\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tInvestigadores del IDIBELL-ICO describen un nuevo mecanismo de resistencia a terapias que impiden la formaci\u00f3n de vasos sangu\u00edneos<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/07\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDescubierto el mecanismo de acci\u00f3n del gen clave para la formaci\u00f3n de los vasos sangu\u00edneos implicado en c\u00e1ncer y malformaciones vasculares<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t21\/11\/2018\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl modelo IDIBELL de innovaci\u00f3n en salud viaja a Barcelona y Jap\u00f3n<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/10\/2018\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"